Mark Skousen
Forecasts & Strategies
Jim Powell
Global Changes & Opportunities Report
Ian Wyatt
Top Stock Insights
J. Royden Ward
Cabot Benjamin Graham Value Letter

4 pharma favorites with 4%+ yields


Bookmark and Share
by Ian Wyatt, editor Daily Profit

Ian WyattWe can debate America's healthcare system; but the simple fact of the matter is that all of us require healthcare at some point in our lives. That's why the healthcare industry is one of the most profitable sectors on the planet.

And with so much cash on hand, healthcare stocks are typically among the most reliable and generous dividend payers on the market. Here's four that pay more than 4% in dividends.

The average dividend yield among healthcare stocks in 2011 was 3.7%, trailing only telecom (5.9% yield) and the ever-reliable utilities (4.1%). Better yet, healthcare stocks posted an average gain of 6.6% last year during a time when the S&P 500 was flat.

Knowing that demand for quality healthcare isn't going anywhere, some of the major players in the healthcare industry should continue to rake in cash even in a down economy.

And as the cash flows, it's reasonable to think that healthcare stocks will remain one of the highest-yielding sectors on the market.

Novartis (NVS) is a multi-national pharmaceutical company based in Switzerland. The company boasts a $131 billion market cap, a profit margin of 14.6%, and $15 billion in operating cash flow.

That's how Novartis manages to pay a generous annual dividend of $2.48 per share - a payout the company has increased every year since 1996. In fact, Novartis' dividend -- now yielding 4.5% -- has more than doubled from $1.15 per share since 2005.

With profits rising for each of the last three years and given the company's diverse inventory of drugs (treating everything from cancer to multiple sclerosis to diabetes), Novartis should continue to be a steady dividend payer for years to come.

Merck & Co. (MRK) bumped its quarterly dividend up to 42 cents per share in December, up from 38 cents a share. it now yields 4.2%;

An agreement to extend its partnership with AstraZeneca -- which sells the widely popular acid reflux drugs Nexium and Prilosec -- for another two years is expected to fetch the company an additional $200 million in revenue.

GlaxoSmithKline (GSK) sells many familiar prescription and over-the-counter drugs GlaxoSmithKline sells. Nicoderm, Advair and Wellbutrin are among them. That's why the British company is currently the No. 2 pharmaceutical manufacturer in the world.

Its 4.8% yield may seem high - but that's been its average for the past five years. That makes GlaxoSmithKline the leading dividend payer by yield among large-cap pharmaceutical stocks.

Eli Lilly & Co. (LLY) has long been one of the global leaders in the pharmaceutical industry. It sells its products in more than 100 countries, and has been in business since 1876.

The company has paid a dividend for almost the entirety of its existence - 126 years. While the company has been slow to grow its dividends of late -- the quarterly payout has been stuck at 49 cents a share since 2009 -- prior to that Eli Lilly had raised its dividends for 42 straight years.

Even if there's no increase in sight, you could do worse than the stock's nearly $2-per-share annual payout and 4.7% yield.

Learn more about this financial newsletter at Ian Wyatt's Daily Profit.

Related articles:


Advertisement
Banner
News Flash

US Natural Gas ETF: On a roll
by Doug Fabian, editor Successful Investing

One area I think is ready for a new buy is natural gas. After experiencing a sharp decline from November through early January, natural gas prices have been on a roll.


Read more...

 

Split buys? HOMB and Noble Energy
by Neil Macneale, editor 2-for-1 Stock Split Newsletter

Each month, we add one stock to our model portfolio based upon those companies that have announced 2-for-1 stock splits; after a meager number of splits over the past year, we have a nice collection of six splits elect from this month.


Read more...


   

WisdomTree targets global bonds
by Mark Salzinger, editor The Investor's ETF Report

While most investors diversify the equity portions of their portfolio with allocations to foreign stocks, few diversify their bond holdings internationally. WisdomTree recently introduced the first ETF to invest in a truly global portfolio of corporate bonds.


Read more...

 

Express Scripts: Obamacare buy
by J. Royden Ward, editor Cabot Benjamin Graham Value Investor

I am attracted to healthcare stocks because the confusion surrounding “ObamaCare” has held healthcare stock prices back. I think Express Scripts (ESRX) is very likely to shine in 2013.


Read more...

 

Hodges: High conviction funds
by Walter Frank, editor MoneyLetter

Over the last two months, Hodges Fund (HDPMX) has made a strong run to the top echelons of our domestic stock fund rankings. And one of its siblings, Hodges Small Cap (HDPSX) has been within the top decline of the small blend category from 2009 through last year, and is in the top 20% this year.


Read more...

 

United Natural: A play on Whole Foods
by Mark Skousen, editor Hedge Fund Trader Alert

We’ve recommended Whole Foods Market (WFM) from time to time, and the stock has moved up sharply in the past three years, but I’d like to suggest an alternative -- one of Whole Foods’ primary suppliers, United Natural Foods (UNFI).


Read more...

 

Timing expert eyes India
by Sy Harding, editor Street Smart Report

The money flow and momentum reversals in India's Bombay Index have now been enough to trigger buy signals on intermediate-term indicators. With this new buy signal, we have added a position in the iShares India 50 ETF (INDY) to our portfolio.


Read more...

 

Value investor goes with Guess
by Charles Mizrahi, editor Hidden Values Alert

Guess?, Inc. (GES) is a holding in our special situation portfolio; its strong product quality has created brand name recognition and a loyal consumer following.


Read more...

 

MGAM: Bingo, lotteries, casinos
by Jim Oberweis, Jr., editor The Oberweis Report

Multimedia Games Holding Company (MGAM) makes innovative gaming systems for Native American and commercial casino operators in North America, lottery operators, and charity and commercial bingo operators.


Read more...

 

Fidelity expert: Bowers' bond bets
by Jack Bowers, editor Fidelity Monitor & Insight

If you’ve been worried that the bond market might take a big hit, you can relax. Indeed, while bond funds may lag stock funds over the next 5-10 years, they still have a decent shot at keeping up with inflation, and they remain an excellent way to cut risk in a blended portfolio.


Read more...

 



Banner



Close
Select Offer: Schwab Options Market Commentary